Memolan

Memantine hydrochloride, the active ingredient in Memolan, is a NMDA receptor antagonist presented as an oral formulation for systemic use. It is indicated for the treatment of Alzheimer’s disease, particularly in patients with moderate to severe cognitive impairment. GNH USA supplies Memolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memolan is an NMDA receptor antagonist used in the management of neurodegenerative conditions affecting cognition and behavior. - Alzheimer’s disease (moderate to severe): improves cognition, global functioning and daily activities. - Behavioral symptoms in Alzheimer’s disease: reduces agitation, aggression and psychotic features. - Dementia associated with Parkinson’s disease: may provide modest improvement in cognitive function.

Memolan may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Hypertension

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Severe hepatic injury - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal ideation or behavior - Psychosis or severe agitation

Prior to initiating Memolan, clinicians should evaluate patient‑specific factors that may influence safety and efficacy. - Renal impairment: adjust dose or monitor plasma levels. - Hepatic dysfunction: use with caution and monitor liver enzymes. - History of seizures: assess risk and consider alternative therapy. - Cardiovascular disease: monitor blood pressure and heart rhythm. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Memolan can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine: additive CNS depression and increased dizziness. - Other NMDA antagonists: risk of excessive neuro‑inhibition.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefit. - Cimetidine or other renal excretion inhibitors: can raise memantine plasma concentrations. - Diuretics: may affect electrolyte balance and blood pressure.